fulvestrant 500 mg

DRUG2 trials

Sponsors

Western Regional Medical Center, Chinese Academy of Medical Sciences

Conditions

Breast CancerER-positive Breast CancerHER2-positive Breast Cancer

Phase 1

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

TerminatedNCT02345772

Western Regional Medical CenterER-positive Breast Cancer, HER2-positive Breast Cancer

Start: 2014-07-31End: 2015-11-30Updated: 2018-02-20

Phase 2

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Chinese Academy of Medical SciencesBreast Cancer

Start: 2015-12-31End: 2020-12-31Target: 148Updated: 2017-01-02

Related Papers

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)

European Journal of Cancer2023-02-1511 citations